News
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz
Vertex baut sein Chief Strategy Office aus, um e-Invoicing und globale Compliance-Initiativen voranzutreiben
Zwei führende Branchenexperten schließen sich dem Chief Strategy Office von Vertex an. Ziel ist es, Produktinnovationen und globale Compliance-Strategien für Kunden zu stärken.
KING OF PRUSSIA, Pa
Die Auswirkungen von Zöllen auf Pharma-Aktien: Eine eingehende Analyse
Eli Lilly Stock: Trump's Tariff Threat Impacts Outlook
Eli Lilly shares could face pressure after Donald Trump reinforced his intention to impose tariffs on imported pharmaceuticals. The Republican president plans to implement duties of "25% or higher"
Der Black Friday kommt früh – mit der Sommer-Sonderaktion von Blue Diamond Resorts
ST. MICHAEL, Barbados, April 09, 2025 (GLOBE NEWSWIRE) -- Nach der überwältigenden Resonanz auf sein jüngstes Angebot legt Blue Diamond Resorts mit der Einführung seiner „Summer Black
Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
Big tech has become known for its big-time use of buybacks. In the last quarter of 2024, Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOG), Meta Platforms (NASDAQ: META), and Microsoft (NASDAQ: MSFT)
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The
Eli Lilly Stock: Legal Battles Over Unauthorized Drug Production
Eli Lilly has intensified its legal campaign against pharmacies producing unauthorized versions of its weight-loss medication tirzepatide. The pharmaceutical giant filed lawsuits against Strive
Regeneron: Der Kampf um globale Gleichheit im Pharmasektor
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately
Rückschlag für Impfstoffaktien nach Rücktritt bei der FDA
Zimmer Biomet Stock: Dividend Payout Set for March 2025
Zimmer Biomet Holdings, a leading medical technology manufacturer specializing in orthopedics, has announced a dividend distribution of $0.24 per share scheduled for late March 2025. This payment
Eli Lilly Stock: Cholesterol Drug Shows Breakthrough Results
Eli Lilly's experimental drug Lepodisiran has delivered impressive results in Phase 2 clinical trials, reducing a genetic risk factor for heart disease by nearly 94 percent. The drug targets
Abbott Laboratories Stock: CE Mark Boosts Cardiac Treatment Innovation
Abbott Laboratories recently experienced a significant upward breakthrough after receiving CE marking for its innovative Volt PFA system, designed to treat atrial fibrillation. This heart rhythm
Pfizer Stock: Probe Into COVID Vaccine Timing Claims
Pfizer shares are facing significant pressure following reports that Manhattan federal prosecutors are investigating serious allegations. The inquiry centers on claims made by British pharmaceutical
Eli Lilly Stock: Outpaces Novo Nordisk in Obesity Market
Eli Lilly's stock has demonstrated remarkable resilience this year, gaining approximately 6% while Danish competitor Novo Nordisk faced significant losses. This divergence in performance reflects a
Merck Stock: Strategic $2B Chinese Partnership Boosts Portfolio
Merck & Co. has entered a landmark licensing agreement with Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals for HRS-5346, an oral inhibitor targeting lipoprotein(a) formation for
Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow
In a market obsessed with the next big growth story, it’s easy to overlook the quiet power of consistency. As tariff turbulence continues, some investors are diverting a portion of their portfolio
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement
AbbVie Stock: Legal Battle Weighs on Share Price
AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00
Bristol-Myers Squibb Aktie: Optimismus prägt Strategie
Die Bristol-Myers Squibb Aktie zeigt sich derzeit in solider Verfassung. Der Kurs des Biopharmazie-Riesen kletterte auf 61,04 USD (Stand: 22. März 2025), was einem Anstieg von 1,01% zum Vortag
Johnson & Johnson Stock: $55 Billion U.S. Investment Signals Growth
Johnson & Johnson (J&J) has announced plans to invest more than $55 billion in the United States over the next four years, representing a 25% increase compared to its spending during the previous